Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- SENTENCE label "For those of COVID-19 related pneumonia, dexamethasone and remdesivir have shown encouraging results, while vaccines are currently being evaluated in phase III trials." provenance.
- SENTENCE label "For those of COVID-19 related pneumonia, dexamethasone and remdesivir have shown encouraging results, while vaccines are currently being evaluated in phase III trials." provenance.
- SENTENCE label "For those of COVID-19 related pneumonia, dexamethasone and remdesivir have shown encouraging results, while vaccines are currently being evaluated in phase III trials." provenance.
- SENTENCE label "For those of COVID-19 related pneumonia, dexamethasone and remdesivir have shown encouraging results, while vaccines are currently being evaluated in phase III trials." provenance.
- SENTENCE label "For those of COVID-19 related pneumonia, dexamethasone and remdesivir have shown encouraging results, while vaccines are currently being evaluated in phase III trials." provenance.
- SENTENCE label "For those of COVID-19 related pneumonia, dexamethasone and remdesivir have shown encouraging results, while vaccines are currently being evaluated in phase III trials." provenance.
- SENTENCE label "For those of COVID-19 related pneumonia, dexamethasone and remdesivir have shown encouraging results, while vaccines are currently being evaluated in phase III trials." provenance.
- SENTENCE label "For those of COVID-19 related pneumonia, dexamethasone and remdesivir have shown encouraging results, while vaccines are currently being evaluated in phase III trials." provenance.
- SENTENCE label "Finally, simulations were performed to predict the antitumor efficacy of dexamethasone (DEX) combined with dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) under various dose regimens, where changing dosing frequency of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) had little effect, while the antitumor efficacy of DEX combined with SUL was predicted to be improved when dexamethasone (DEX) was given more frequently." provenance.
- SENTENCE label "Finally, simulations were performed to predict the antitumor efficacy of dexamethasone (DEX) combined with dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) under various dose regimens, where changing dosing frequency of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) had little effect, while the antitumor efficacy of DEX combined with SUL was predicted to be improved when dexamethasone (DEX) was given more frequently." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "When trigeminal ganglia (TG) explants were incubated with media containing dexamethasone to stimulate reactivation, significantly fewer β-catenin+ trigeminal ganglia (TG) neurons were detected." provenance.
- SENTENCE label "When trigeminal ganglia (TG) explants were incubated with media containing dexamethasone to stimulate reactivation, significantly fewer β-catenin+ trigeminal ganglia (TG) neurons were detected." provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.